Mercados españoles cerrados

Almirall, S.A. (ALM.MC)

MCE - MCE Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
8,39+0,03 (+0,30%)
Al cierre: 05:35PM CEST

Almirall, S.A.

Ronda General Mitre, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1904

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Carlos Gallardo PiquéCEO, President, Member of Management Board & Chairman of the Board50kN/A1972
Mr. Michael McClellanCFO & Member of Management BoardN/AN/A1972
Mr. Eloi Crespo CerveraChief Industrial Operations Officer & Member of Management BoardN/AN/AN/A
Mr. Esteve Conesa PanicotChief People & Culture Officer and Member of Management BoardN/AN/AN/A
Dr. Volker KoscielnyChief Medical Officer & Member of Management BoardN/AN/AN/A
Dr. Karl ZiegelbauerChief Scientific Officer & Member of Management BoardN/AN/AN/A
Mr. Paolo CioniniChief Commercial Officer Europe & International and Member of Management BoardN/AN/AN/A
Ms. Isabel Cristina GomesCompany Vice Secretary,Chief Legal Officer, General Counsel & Member of Management BoardN/AN/AN/A
Ms. Mercedes Diz LopezChief Marketing Officer & Member of Management BoardN/AN/AN/A
Mr. Pablo Divasson del FraileSenior Director of Investor RelationsN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2015 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Gobierno corporativo

El ISS Governance QualityScore de Almirall, S.A., a día 1 de abril de 2024, es 4. Las puntuaciones base son Auditoría: 5; Tablero: 4; Derechos de los accionistas: 3; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.